Tweet
Triangle Business Journal |
Pozen gets another FDA cold shoulder for its cardio drugs FierceBiotech The FDA again rejected Pozen's ($POZN) pair of treatments designed to help patients deal with cardiovascular disease, citing the same third-party manufacturing issues that tanked the last application. Pozen claims the supplier has since rectified those ... Pozen receives second CRL for Yosprala, shares drop (POZN)Seeking Alpha FDA rejects Pozen's aspirin drug for second time; shares plunge 20%Triangle Business Journal Pozen says FDA rejects two forms of its lead drug, shares fallKFGO MarketWatch all 12 news articles » |
More...